BioSpace News Archive

Zimmer Biomet Holdings, Inc., a global medical technology leader, announced plans to unveil the latest enhancements to ZBEdge™ Dynamic Intelligence™ at the American Academy of Orthopaedic Surgeon’s 2023 Annual Meeting in Las Vegas.

Alpha-9 Theranostics, a clinical stage biotechnology company developing differentiated and highly targeted radiopharmaceuticals, announced the appointment of Jutta Wanner, Ph.D. as Senior Vice President of Drug Discovery.

Nevro Corp. (NYSE: NVRO) today announced that it has now initiated the U.S. full market launch of its HFX iQ spinal cord stimulation (SCS) system, following the completion of a successful limited market release.

Ionis Pharmaceuticals (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for eplontersen, an investigational antisense medicine for the treatment of people living with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced the first customer shipments of Revio long-read sequencing systems will commence on March 8, 2023.

Exscientia plc (Nasdaq: EXAI) today announced a new collaboration with Charité – Universitätsmedizin Berlin (Charité) to utilise Exscientia’s AI-driven precision medicine platform in haematological cancers.

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2022 financial results and provided business updates.

908 Devices Inc., a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, reported financial results for the quarter and full year ended December 31, 2022.

Rapport Therapeutics, Inc., a clinical-stage biotechnology company dedicated to the discovery and development of precision medicines for neurological disorders, launched with a $100 million Series A financing from Third Rock Ventures, ARCH Venture Partners and Johnson & Johnson Innovation – JJDC, Inc.

Flagship Pioneering, the bioplatform innovation company, unveiled Ampersand Biomedicines, a company creating programmable medicines that are safer, more tolerable, and effective by acting at the site of disease.